Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
Options
BORIS DOI
Date of Publication
March 2025
Publication Type
Article
Division/Institute
Contributor
Yang, Yangyupei | |
Knoll, Maria Deloria | |
Herbert, Carly | |
Bennett, Julia C | |
Feikin, Daniel R | |
Hetrich, Marissa K | |
Zeger, Scott L | |
Kagucia, Eunice W | |
Xiao, Melody | |
Cohen, Adam L | |
van der Linden, Mark | |
du Plessis, Mignon | |
Yildirim, Inci | |
Winje, Brita A | |
Varon, Emmanuelle | |
Valenzuela, Maria Teresa | |
Valentiner-Branth, Palle | |
Steens, Anneke | |
Scott, J Anthony | |
Savrasova, Larisa | |
Sanz, Juan Carlos | |
Khan, Aalisha Sahu | |
Oishi, Kazunori | |
Nzoyikorera, Néhémie | |
Nuorti, J Pekka | |
Mereckiene, Jolita | |
McMahon, Kimberley | |
McGeer, Allison | |
Mackenzie, Grant A | |
MacDonald, Laura | |
Ladhani, Shamez N | |
Kristinsson, Karl G | |
Kleynhans, Jackie | |
Kellner, James D | |
Jayasinghe, Sanjay | |
Ho, Pak-Leung | |
Hammitt, Laura L | |
Guevara, Marcela | |
Gilkison, Charlotte | |
Gierke, Ryan | |
Desmet, Stefanie | |
De Wals, Philippe | |
Dagan, Ron | |
Colzani, Edoardo | |
Ciruela, Pilar | |
Chuluunbat, Urtnasan | |
Chan, Guanhao | |
Camilli, Romina | |
Bruce, Michael G | |
Brandileone, Maria-Cristina C | |
Ampofo, Krow | |
O'Brien, Katherine L | |
Hayford, Kyla |
Subject(s)
Series
Journal of Infection
ISSN or ISBN (if monograph)
1532-2742
0163-4453
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
39864526
Description
Background
Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.Methods
The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5-17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types.Results
Analyses included 10,168 cases <5y from PCV13 sites and 2,849 from PCV10 sites, 3,711 and 1,549 for 5-17y and 29,187 and 5,653 for ≥18y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 4874% across products and PCV7 impact strata for children <5y, 3562% for 5-17y and 036% for ≥18y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5y: 96100%; 5-17y: 7785%; ≥18y: 7385%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups.Conclusion
Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.Methods
The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5-17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types.Results
Analyses included 10,168 cases <5y from PCV13 sites and 2,849 from PCV10 sites, 3,711 and 1,549 for 5-17y and 29,187 and 5,653 for ≥18y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 4874% across products and PCV7 impact strata for children <5y, 3562% for 5-17y and 036% for ≥18y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5y: 96100%; 5-17y: 7785%; ≥18y: 7385%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups.Conclusion
Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| 1-s2.0-S0163445325000209-main.pdf | text | Adobe PDF | 3.94 MB | Attribution (CC BY 4.0) | published |